Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7174872

Cc1cc(C(C)(C)C)cc(C)c1C(=O)Pc1ccc(Oc2ccccc2)cc1Oc1ccccc1.[Li]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ SRD5A2 P31213 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ FFAR1 O14842 2/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.34
▸ FABP1 P07148 1/20 0.34
▸ FAAH O00519 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ AKR1C3 P42330 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174868 0.98 RAF1 (0.37) RAF1NPC1RAB9APOLBCYP2C9
Lithium SCHEMBL7182271 0.89 SRD5A2 (0.38) RAB9ASRD5A2MEN1LMNAKMT2A
SCHEMBL7180151 0.88 RAF1 (0.40) RAF1NPC1RAB9APOLBCYP2C9
Lithium SCHEMBL7175882 0.88 MEN1 (0.41) NPC1RAB9APOLBSRD5A2MEN1
SCHEMBL7182259 0.87 PTGS1 (0.38) SRD5A2MEN1KMT2AKDM4EHSD17B10
SCHEMBL7175874 0.85 MEN1 (0.44) NPC1RAB9APOLBSRD5A2MEN1
Lithium SCHEMBL7185604 0.85 SRD5A2 (0.36) RAB9ASRD5A2MEN1LMNAKMT2A
SCHEMBL7180880 0.83 KDM4E (0.36) RAF1NPC1RAB9ASRD5A2L3MBTL1
SCHEMBL7185593 0.82 PTGS1 (0.36) RAB9ASRD5A2MEN1LMNAKMT2A
SCHEMBL7183728 0.82 SRD5A2 (0.39) RAF1NPC1RAB9APOLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 RAF1 1246/4885NPC1 772/4885RAB9A 1818/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 RAF1 1700/4885NPC1 872/4885RAB9A 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.